These findings are still being studied, but they suggest that patients with eye conditions, such as glaucoma, should proceed with caution when using semaglutide
Promotesradiant, even-toned skinand helps reduce post-inflammatory pigmentation
503 Another trial confirmed that ustekinumab had a favorable safety profile when applied to UC patients for 1 year, with adverse event rates typically comparable to those of placebo
In TRIUMPH-1, the pivotal Phase 3 general-obesity trial (2,339 participants), the topline results reported on May 21, 2026 showed average weight loss at 80 weeks of 19.0% on 4 mg, 25.9% on 9 mg, and 28.3% (70.3 lbs) on 12 mg, versus 2.2% on placebo
Expert Rev
The science behind semaglutide-induced diarrhea Contrary to popular assumptions, semaglutide doesn't cause diarrhea through a single mechanism